Depressive Symptomatology Is Associated With Smaller Reductions in Drug Cue Reactivity During Extended-Release Naltrexone Treatment of Opioid Use Disorder
The Journal of Clinical Psychiatry · 2023
DOI: 10.4088/jcp.22br14567 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Psychiatry, 2023. Verfasst von Zhenhao Shi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. Hauptthemen laut MEDLINE: Naltrexone, Opioid-Related Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NIAAA NIH HHS.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
T he high incentive value attributed to a drug in substance use disorders leads to the heightened dopaminergic responses to drug-related conditioned stimuli (ie, cue reactivity), 1 stimulating drug-seeking behavior and promoting relapse. 2 The nucleus accumbens (NAcc) is the key brain region implicated in cue reactivity in general.Specifically, in opioid use disorder (OUD), greater NAcc response to opioid drug cues has been associated with heavier drug use.3 The once-monthly injectable extended-release opioid antagonist naltrexone (XR-NTX) is an effective relapse prevention medication for OUD 4,5 that significantly reduces NAcc cue reactivity.6,7 Depression and OUD are highly comorbid, 8,9 and both involve endogenous opioid dysregulation.10,11 Patients with more severe depressive symptoms show poorer response to OUD treatment.[12][13][14] Here, we used functional magnetic resonance imaging (fMRI) to test the hypothesis that depressive symptomatology in OUD is associated with reduced sensitivity of subjective or neural indices of drug cue reactivity to the XR-NTX treatment of OUD. MethodsWe performed a secondary analysis on a previously described dataset.6 Briefly, 23 detoxified OUD patients (9 female; 21-47 years old) were offered up to 3 monthly XR-NTX injections.Participants completed pre-treatment fMRI before the first injection and on-treatment fMRI approximately 2 weeks after the first injection.Each fMRI session included a cue reactivity task that presented drugrelated, sexual, aversive, and neutral images.Before and after the task, participants reported craving for opioids on a 10-point scale (0 = none, 9 = extremely).Cue-induced craving was indexed by the change from before to after the task.The Beck Depression Inventory (BDI), which demonstrates good reliability and validity in the OUD population, 15,16 was administered approximately 1 week after the first injection.Preprocessed fMRI data were analyzed by modeling each stimulus category.The NAcc was defined as the a priori region of interest.Neural activity was evaluated by contrasting the drug, sexual, and aversive conditions with the neutral condition.Pearson correlation was performed between BDI scores and changes in cue-induced craving and NAcc drug cue reactivity (on-treatment minus pre-treatment).We also tested the correlation for sexual and aversive stimuli.Wholebrain analysis explored correlation in other brain regions.17 See the Supplementary Material and Shi et al 6 for additional details on the methods. ResultsParticipants' BDI scores ranged from 0 (no depression) to 24 (moderate depression) (mean ± SD = 9.91 ± 6.22).A higher BDI score was associated with smaller reductions in cue-induced craving and NAcc cue reactivity at the ROI level (r = 0.44 and 0.50, P = .035and .014; Figure 1) from pre-treatment to on-treatment.BDI score was not correlated with changes in NAcc response to sexual or aversive stimuli, (r = 0.21 and 0.07, P = .34and .75).Whole-brain analysis did not show correlation with BDI score in other regions.See the Supplementary Material for additional results. DiscussionGreater depressive symptoms were associated with smaller reductions in cue-induced craving and NAcc drug cue reactivity during XR-NTX treatment, suggesting that depression may hamper XR-NTX's ability to restore normal incentive salience processing.The lack of correlation between depressive symptoms and changes in NAcc response to the non-drug stimuli is consistent with our prior observation that XR-NTX effect was specific to drug cues.6 Although there is no evidence of XR-NTX causing depression, [18][19][20] patients with greater depressive symptoms show more drug-related thoughts during XR-NTX treatment.21 Our data corroborate this finding and point to NAcc as a key region mediating the impact of depressive symptoms on XR-NTX effectiveness.Given that depression and OUD are highly comorbid, 9 interventions targeting depressive symptoms may improve XR-NTX treatment success.22 Study limitations include small sample size, potential confounds in the visual stimulus parameters, and limited number of follow-up timepoints (see Supplementary Material).Future studies are needed to confirm our findings and explore other factors that contribute to individual differences in relapse vulnerability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
- Corresponding author: Daniel D. Langleben, MD, 3535 Market St Ste 500, Philadelphia, PA 19104 (langlebe@pennmedicine.upenn.edu).
Förderung
- NIDA NIH HHS
- NIAAA NIH HHS
Zitieren
APA
Shi, Z., Li, X., Kampman, K. M., Childress, A. R., Wiers, C. E., & Langleben, D. D. (2023). Depressive Symptomatology Is Associated With Smaller Reductions in Drug Cue Reactivity During Extended-Release Naltrexone Treatment of Opioid Use Disorder. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.22br14567
Vancouver
Shi Z, Li X, Kampman KM, Childress AR, Wiers CE, Langleben DD. Depressive Symptomatology Is Associated With Smaller Reductions in Drug Cue Reactivity During Extended-Release Naltrexone Treatment of Opioid Use Disorder. The Journal of Clinical Psychiatry. 2023. doi:10.4088/jcp.22br14567
BibTeX
@article{Shi2023,
author = {Shi, Zhenhao and Li, Xinyi and Kampman, Kyle M and Childress, Anna Rose and Wiers, Corinde E and Langleben, Daniel D},
title = {Depressive Symptomatology Is Associated With Smaller Reductions in Drug Cue Reactivity During Extended-Release Naltrexone Treatment of Opioid Use Disorder},
journal = {The Journal of Clinical Psychiatry},
year = {2023},
doi = {10.4088/jcp.22br14567}
}
EUVIMED